Présentation de l'entreprise
NeuroOne Medical Technologies Corporation, operating under the ticker NMTC, specializes in delivering specialized medical technology solutions for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording within the United States market. The company further expands its portfolio by offering therapeutic interventions for spinal cord stimulation, brain stimulation, and drug delivery systems. This entity functions within the healthcare sector, specifically categorized under the medical devices industry, which encompasses the manufacturing and distribution of equipment essential for diagnostic procedures and patient treatment. In terms of scale, the corporation holds a market capitalization of $40.30 million and generates annual revenue totaling $11.72 million, while maintaining a workforce of 18 employees. These valuation and revenue figures indicate that NeuroOne operates as a micro-cap entity with a relatively small operational footprint, suggesting a niche focus on high-value, specialized medical instrumentation rather than mass-market volume sales.
Santé financière
The company reports trailing twelve-month revenue of $11.72 million, a net income of -$6,828,586, and an EBITDA of -$7,382,912. The substantial gap between the positive revenue figure and the significant net loss reveals a highly aggressive cost structure where operating expenses and other deductions heavily outweigh gross profitability, resulting in a net income that is nearly 58% more negative than the EBITDA figure. Free cash flow stands at -$3,917,580, indicating that the company is currently burning cash to fund operations and capital expenditures, which limits its immediate financial flexibility and ability to fund organic expansion without external financing. The gross margin is recorded at 22.0%, reflecting the portion of revenue remaining after direct production costs, while the operating margin of -59.0% and profit margin of -58.3% highlight severe inefficiencies in managing overhead costs relative to sales volume. The balance sheet shows a cash position of $3.56 million against total debt of $237,377, supported by a debt-to-equity ratio of 3.71, which suggests a leveraged capital structure despite the nominal debt amount being low relative to cash reserves. A current ratio of 6.41 indicates strong short-term liquidity, as the company possesses more than six times the current assets necessary to cover its short-term liabilities. Return on Equity is calculated at -146.3% and Return on Assets at -63.4%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and the company's asset base, likely due to the stage of business development or recent strategic pivots.
Évaluation de la valorisation
Valuation multiples for NeuroOne show a P/E Ratio (TTM) as N/A due to losses, while the Forward P/E stands at -2.84, implying that the market anticipates earnings will remain negative in the near term based on current projections. The Price to Book ratio is 6.26, suggesting that the market values the company's equity at a significant premium of over six times its accounting book value, which is common for technology firms with intangible assets not fully captured on the balance sheet. Alternative valuation metrics such as a Price to Sales ratio of 3.44 and an EV/EBITDA of -4.99 further illustrate that the stock is priced based on revenue multiples rather than earnings power, reflecting investor expectations of future profitability recovery. The stock has traded between a 52-week high of $1.16 and a 52-week low of $0.40, positioning the current trading price within this established volatility range and reflecting the speculative nature of the investment. The Beta value of 0.58 indicates that the stock's price volatility is less than 58% of the broader market's movements, suggesting it may act as a lower volatility play relative to the S&P 500 during periods of market turbulence.
Growth & Income
Revenue growth year-over-year is recorded at -11.7%, while earnings growth is listed as N/A due to the company's lack of profitability, meaning earnings are not growing at all but rather contracting as losses accumulate. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that all available earnings are retained or used to cover losses rather than being distributed to shareholders. This reinvestment strategy is typical for pre-profitability medical device companies that prioritize funding research and development over returning capital to investors. The overall growth and income profile characterizes NeuroOne as a high-risk, low-income asset with negative revenue momentum and no current income generation for shareholders.